Podcasts about Drug discovery

Welcome back to Impact Theory with Tom Bilyeu. In this episode, I sit down with my co-host Drew to rip into one of the most turbulent weeks in global politics and economics we've seen in a long time. We break down not just the moves, but the motives and the possible massive consequences behind Trump's high-octane foreign policy—from slashing tariffs with China and locking in a colossal Saudi investment deal, to taking the unprecedented step of targeting Big Pharma with an executive order to lower drug prices. We get into whether all this fast action is actually helping America or just stirring up more chaos. Are we leveraging our moment, or just getting played by the likes of Xi and Putin? Does tough talk and bold negotiating end with real results for America, or are we setting ourselves up for long-term headaches, especially with midterms on the horizon? Then we peel back the layers on some of the rawest culture war issues, from immigration crackdowns in the UK, the controversy about a Muslim-majority city in Texas, to the viral video of world leaders acting out-of-pocket on a train to Kiev. SHOWNOTES 00:00 – China's 90-Day Tariff Pause: Progress or a Lifeline for Xi? 01:42 – Negotiation Tactics: Deal-Making or Getting Played? 03:48 – The Real Purpose of the 90-Day Pause 05:16 – China Can Print Money: Central Banks and Sinister Power 07:13 – Trump's Aggressive Approach: Productive Chaos? 09:14 – What's Actually Getting Done—And What's Just PR? 10:57 – Accepting a Gold-Plated Jet: Smart Move or Trojan Horse? 13:29 – Why “Greedy Capitalist” Isn't Always an Insult 15:51 – When Deals Cross the Line 18:38 – Global Trade Rebalancing: Is Win-Win Possible with China? 21:17 – Breaking Down the $600 Billion Saudi Deal 24:23 – Why Innovation Stalled—and What Competition With China Could Spark 25:54 – Instilling Inspiration vs. Self-Loathing in American Youth 29:31 – Price Fixing Big Pharma: Popular, but Ultimately Dangerous? 32:15 – Central Banks: The Fungus Beneath the Free Market 36:07 – How Drug Pricing Actually Gets Decided (and Where It Breaks Down) 39:04 – Why Price Fixing Backfires 42:36 – Cigarettes, Prisons, and the True Nature of Supply & Demand 47:14 – Drug Discovery, Innovation, and Unintended Consequences 54:58 – Culture Wars: Immigration Policy in the UK and the US 58:34 – Building the Modern Middle East—Without Western Intervention 60:48 – The Harsh Realities of Assimilation and Cultural Conflict 65:35 – What Happens When Zoning and Religion Collide? 71:19 – Demographics as Destiny: What History Teaches About Outnumbering 74:00 – Respecting Law, Freedom, and What It Means to Be American CHECK OUT OUR SPONSORS ButcherBox: Ready to level up your meals? Go to ⁠https://ButcherBox.com/impact⁠ to get $20 off your first box and FREE bacon for life with the Bilyeu Box! Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Shopify: Sign up for your one-dollar-per-month trial period at ⁠https://shopify.com/impact⁠ Netsuite: Download the CFO's Guide to AI and Machine Learning at ⁠https://NetSuite.com/THEORY⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at ⁠https://mintmobile.com/impact.⁠  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. Learn more about your ad choices. Visit megaphone.fm/adchoices

What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines. With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTsAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer's treatments”, “The start-up disrupting the field of women's reproductive health” and “India: Why is the country ramping up drug discovery research?” Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer's disease. The focus of the trial is to test Cognition Therapeutics' experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. In the first article, Reece Armstrong speaks to Lisa Ricciardi, CEO of Cognition Therapeutics, to learn about what the company hopes to achieve with CT1812. In the second article, DDW's Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute's (BII) Venture Lab acceleration programme, about the lack of innovation in women's reproductive health and the company's plans to fill the vacuum. In the third article, I take a deeper look into why India is ramping up drug discovery research, and explores the country's innovation hubs of interest.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs permit is a screening of new drugs, of whatever entity – chemical or biological – to better predict how they will behave when put into a patient, says Kostriezewski. From metabolic to neurological diseases, as well as oncological – the applicability of organ-on-a-chip technologies is wide ranging, and regulators have been taking a more active role in trying to understand their role and value, and thereby validate their contextual usage at a future point. Nonetheless, already data is accepted today using this new approach, explains Kostriezewski, providing further insights on the landscape as market adoption continues to grow globally. You can listen to episode 174a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here

The Future of AI in Pharma & Biotech Research #aiinbiotech #pharmaresearch #drugdiscovery AI is fundamentally changing the way biotech and pharmaceutical research happens. From analyzing vast datasets to accelerating drug discovery, AI-powered solutions are making labs smarter, faster, and more efficient. But how does it actually work? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit with Liran Belenzon, CEO of BenchSci, to explore how AI reshapes pharmaceutical research. We discuss:✅ The biggest challenges of working with scientific data✅ Why big pharma companies prefer AI-powered platforms over in-house solutions✅ How multimodal AI enhances lab efficiency and accelerates drug developmentLiran also shares his journey from being an MBA student to leading a company that works with 12 of the world's top 20 pharma companies. If you're curious about the intersection of AI, biotech, and research, this episode is a must-watch. Let's talk about the future of AI in biotech. What excites you the most? Let me know in the comments. Links from this episode:✅ Get to know more about Liran Belenzon: https://www.linkedin.com/in/liranbelenzon ✅ Learn more about BenchSci: https://www.benchsci.com ✅ Follow BenchSci for updates on AI in biotech: https://ca.linkedin.com/company/benchsci 

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”. In the first article, Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. In the second article, Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio, provide an industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development.

"I was born and raised in a developing country. I was born and raised in Pakistan. And it's very interesting when you're born in a developing country. That's your world. Right? That's all you know." In this episode of The Biotech Startups Podcast, we delve into Rabia Khan's remarkable journey from her childhood in Pakistan to founding Serna Bio, an AI-enabled drug discovery company. Rabia shares how her early experiences in a developing country, her aunt's battle with schizophrenia, and the sequencing of the human genome in 2000 sparked her passion for genetics and healthcare. She recounts how her career options were either medicine or engineering, setting her on a path that would eventually lead to pioneering work at the intersection of AI and biotechnology. Rabia describes her transition to McGill University in Montreal, facing the shock of -40°C weather with only a leather jacket while navigating life as an international student with no support system. Despite these challenges, she pursued dual interests in biology and economics, finding her first research opportunity in a schizophrenia lab where she started by pipetting water and washing dishes.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura” and “From the Top: Adele Hannigan, Antibody Analytics”. In the first article, Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company's approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). In the second article, Megan Thomas looked at a day in the life of Giusy Di Conza, Head of Research at iOnctura. In the third article, Megan Thomas shines a spotlight on Adele Hannigan, CBO for Antibody Analytics, which has since been rebranded as RoukenBio.

Welcome to an eye-opening conversation at the intersection of artificial intelligence and biotechnology. In this episode, we explore how AI is redefining protein design, accelerating drug discovery, and personalizing medicine at scale.Joining us is Brian Keane, Chairman of the Board at Diagen AI — a trailblazing Canadian company using AI-powered molecular modeling to revolutionize therapeutic development. With a background in capital markets and a passion for next-gen healthtech, Brian shares how Diagen AI is not only optimizing drug development timelines, but also rescuing failed trials, creating novel diagnostics, and designing next-generation peptides and proteins.

In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Alfred Botchway, CEO of Attentive Science, to discuss his journey in biomedical science and the groundbreaking work being done at the intersection of AI, non-clinical safety, and drug discovery. Dr. Botchway shares his insights on the role of AI in refining toxicology studies, how stress impacts human health, and his experience founding companies like Xenometrics and Attentive Science.The conversation dives deep into the complexities of Good Laboratory Practices (GLP), the importance of regulatory standards, and the exciting research happening in anxiety and PTSD treatments. Dr. Botchway also discusses the future of biomedical research, the need for greater collaboration between academia and industry, and how innovations in sample collection are transforming clinical trials.Whether you're interested in AI, biomedical innovation, or the future of drug discovery, this episode offers valuable insights from a leader shaping the industry.Don't forget to subscribe and let us know your thoughts in the comments below!Dr. Alfred Botchwayhttps://www.linkedin.com/in/alfred-botchway-41b01a6/CEO of Attentive Science: https://www.attentivescience.com/ Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/ 00:00 Introduction to BioTalk Unzipped02:32 Dr. Alfred Botchway's Journey in Biomedical Science03:48 Challenges Founding and Growing Xenometrics07:30 Starting Attentive Science: A New Venture09:37 Love of the Work - Variations10:26 The Role of AI in Non-Clinical Safety Assessments13:04 The Three Rs: Replace, Reduce, Refine, and AI15:46 Regulatory Standards and Good Laboratory Practices20:42 New News! - Research on Anxiety and Drug Discovery27:07 Cortical Stimulation and Stress Management27:45 Bridging Academia and Industry29:26 Engaging the Next Generation in Science32:42 The Value of Vocational Training in Science34:47 Community Involvement and Giving Back37:00 Cultural Influences on Leadership42:39 Global Expansion and Strategic Goals48:41 Innovations in Sample Collection for Clinical TrialsDigital Twin Episodes reference with Tomas Helikar:Transforming Immunology: The Promise of Digital Twins with Dr. Tomáš Helikarhttps://youtu.be/jTM_Zlt3wxU Digital Twins: The Future of Drug Discovery with Dr. Tomáš Helikarhttps://youtu.be/NM5X0jTd6UA

In this episode of Crazy Wisdom, Stewart Alsop speaks with German Jurado about the strange loop between computation and biology, the emergence of reasoning in AI models, and what it means to "stand on the shoulders" of evolutionary systems. They talk about CRISPR not just as a gene-editing tool, but as a memory architecture encoded in bacterial immunity; they question whether LLMs are reasoning or just mimicking it; and they explore how scientists navigate the unknown with a kind of embodied intuition. For more about German's work, you can connect with him through email at germanjurado7@gmail.com.Check out this GPT we trained on the conversation!Timestamps00:00 - Stewart introduces German Jurado and opens with a reflection on how biology intersects with multiple disciplines—physics, chemistry, computation.05:00 - They explore the nature of life's interaction with matter, touching on how biology is about the interface between organic systems and the material world.10:00 - German explains how bioinformatics emerged to handle the complexity of modern biology, especially in genomics, and how it spans structural biology, systems biology, and more.15:00 - Introduction of AI into the scientific process—how models are being used in drug discovery and to represent biological processes with increasing fidelity.20:00 - Stewart and German talk about using LLMs like GPT to read and interpret dense scientific literature, changing the pace and style of research.25:00 - The conversation turns to societal implications—how these tools might influence institutions, and the decentralization of expertise.30:00 - Competitive dynamics between AI labs, the scaling of context windows, and speculation on where the frontier is heading.35:00 - Stewart reflects on English as the dominant language of science and the implications for access and translation of knowledge.40:00 - Historical thread: they discuss the Republic of Letters, how the structure of knowledge-sharing has evolved, and what AI might do to that structure.45:00 - Wrap-up thoughts on reasoning, intuition, and the idea of scientists as co-evolving participants in both natural and artificial systems.50:00 - Final reflections and thank-yous, German shares where to find more of his thinking, and Stewart closes the loop on the conversation.Key InsightsCRISPR as a memory system – Rather than viewing CRISPR solely as a gene-editing tool, German Jurado frames it as a memory architecture—an evolved mechanism through which bacteria store fragments of viral DNA as a kind of immune memory. This perspective shifts CRISPR into a broader conceptual space, where memory is not just cognitive but deeply biological.AI models as pattern recognizers, not yet reasoners – While large language models can mimic reasoning impressively, Jurado suggests they primarily excel at statistical pattern matching. The distinction between reasoning and simulation becomes central, raising the question: are these systems truly thinking, or just very good at appearing to?The loop between computation and biology – One of the core themes is the strange feedback loop where biology inspires computational models (like neural networks), and those models in turn are used to probe and understand biological systems. It's a recursive relationship that's accelerating scientific insight but also complicating our definitions of intelligence and understanding.Scientific discovery as embodied and intuitive – Jurado highlights that real science often begins in the gut, in a kind of embodied intuition before it becomes formalized. This challenges the myth of science as purely rational or step-by-step and instead suggests that hunches, sensory experience, and emotional resonance play a crucial role.Proteins as computational objects – Proteins aren't just biochemical entities—they're shaped by information. Their structure, function, and folding dynamics can be seen as computations, and tools like AlphaFold are beginning to unpack that informational complexity in ways that blur the line between physics and code.Human alignment is messier than AI alignment – While AI alignment gets a lot of attention, Jurado points out that human alignment—between scientists, institutions, and across cultures—is historically chaotic. This reframes the AI alignment debate in a broader evolutionary and historical context, questioning whether we're holding machines to stricter standards than ourselves.Standing on the shoulders of evolutionary processes – Evolution is not just a backdrop but an active epistemic force. Jurado sees scientists as participants in a much older system of experimentation and iteration—evolution itself. In this view, we're not just designing models; we're being shaped by them, in a co-evolution of tools and understanding.

Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages.  By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease."    "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker."  #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers  sapient.bio Download the transcript here

Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages.  By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease."    "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker."  #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers  sapient.bio Listen to the podcast here

OpenAI has successfully raised $40 billion in what is believed to be the largest private technology funding round ever, boosting its valuation to $300 billion. This funding round was predominantly led by the Japanese investment firm SoftBank, which has now surpassed Microsoft as OpenAI's largest investor. Despite the impressive growth in revenue and user base, OpenAI continues to face challenges in achieving profitability, as it invests heavily in infrastructure and user acquisition. The company has announced plans to release its first open-weight language model since 2019, marking a strategic shift to adapt to competitive pressures from open-source alternatives.The podcast also highlights significant advancements in AI applications across various sectors. Researchers are leveraging AI to accelerate drug repurposing, enabling faster exploration of treatment options for patients with limited choices. American Express has integrated AI into its internal IT support, achieving a remarkable reduction in IT escalations and enhancing travel assistance for its elite customers. These examples illustrate the potential of AI to deliver tangible business value and improve operational efficiency.However, the integration of AI is not without its challenges. Bloomberg News has faced difficulties in generating accurate AI summaries for articles, leading to corrections and concerns about the reliability of AI-generated content. This underscores the importance of maintaining quality control and human oversight in AI applications, particularly in fields like journalism where accuracy is paramount.The episode concludes with a discussion on trends towards simplifying complex processes in business. Innovations such as rapid business valuation tools, enhanced customer communication through Rich Communication Services, and streamlined cyber insurance solutions reflect a broader movement to improve efficiency and accessibility in various industries. These developments highlight the ongoing evolution of technology and its impact on business operations, emphasizing the need for strategic implementation of AI and other technological advancements. Three things to know today 00:00 OpenAI's Rollercoaster Ride: Big Money, Open Models, and Profit Puzzles06:29 AI Wins and Woes: Curing Disease, Solving Problems, and Sometimes Missing the Mark10:41 MSPs Get a Boost: Faster Insights, Smoother Communication, and Insurance Made Easy  Supported by:  https://getnerdio.com/nerdio-manager-for-msp/  Join Dave April 22nd to learn about Marketing in the AI Era.  Signup here:  https://hubs.la/Q03dwWqg0 All our Sponsors: https://businessof.tech/sponsors/ Do you want the show on your podcast app or the written versions of the stories? Subscribe to the Business of Tech: https://www.businessof.tech/subscribe/Looking for a link from the stories? The entire script of the show, with links to articles, are posted in each story on https://www.businessof.tech/ Support the show on Patreon: https://patreon.com/mspradio/ Want to be a guest on Business of Tech: Daily 10-Minute IT Services Insights? Send Dave Sobel a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/businessoftech Want our stuff? Cool Merch? Wear “Why Do We Care?” - Visit https://mspradio.myspreadshop.com Follow us on:LinkedIn: https://www.linkedin.com/company/28908079/YouTube: https://youtube.com/mspradio/Facebook: https://www.facebook.com/mspradionews/Instagram: https://www.instagram.com/mspradio/TikTok: https://www.tiktok.com/@businessoftechBluesky: https://bsky.app/profile/businessof.tech

How is the pharmaceutical industry evolving to meet the world's biggest health challenges? In this episode, Nicolai Tangen sits down with Emma Walmsley, CEO of GSK, for an insightful conversation about the future of pharmaceuticals. They discuss GSK's latest advances in cancer treatments, HIV therapies, and respiratory medicine, as well as the role of AI in speeding up drug discovery. Emma also shares her thoughts on navigating change, transforming company culture, and the role of curiosity in staying motivated. Tune in!In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company's collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The conversation explores the evolution of mass spectrometry platforms, highlighting the robustness and sensitivity of Sciex's 7500+ system and the increasing role of AI in streamlining data analysis. Dawn and John reflect on the challenges of adopting new technologies in regulated environments, emphasizing the balance between innovation and practical application.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of drug-induced arrhythmias during drug discovery”.  In the first article, Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. In the second article, Dr Mark Treherne, Dr Jack Scannell and Dr Richard Saumarez answer the question: Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods?

Synopsis: How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture. Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify's groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies. He also dives deep into biotech innovation, smart capital strategy, M&A trends, and the power of hiring the right talent. Whether you're a biotech founder, investor, or science enthusiast, this episode is packed with insights on building, funding, and scaling a biotech startup in today's competitive landscape. Biography: Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify Pharma and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development, and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from the University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.

This is the latest episode of the free DDW narrated podcast, titled “Critical tools that support drug discovery and development”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “You think you need an ELN… but are you asking the right questions?” and “Big data: Charting a new path to drug discovery and development”. In the first article, Matt Clifford, Director of Research and Innovation Strategy at IDBS, discusses the questions that need to be asked if you're considering an ELN.  In the second article, Tim Lowery, President of JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology.

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss his groundbreaking work in drug discovery using artificial intelligence. Dr. Gupta shares insights from his career, including his leadership in combating the opioid crisis, and explains how AI and machine learning are transforming the speed, cost, and success rates of drug development.

Send us a textThe integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well.In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations, dramatically accelerating time to market and increasing throughput.Key takeaways from the conversation with Yossi Quint:AI's Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows.The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches, emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors.Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward.With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need.If you want to learn more, here are a few standout conversations on AI's impact on bioprocessing with some incredible experts:Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza FarahaniEpisodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiEpisodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars BrandénEpisodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David SchönauerEpisodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma AlispahicConnect with Yossi Quint:LinkedIn: https://www.linkedin.com/in/yossi-quintArk: https://www.ark-biotech.comNext step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.

The future of medicine is being shaped by technology, and few companies are pushing the boundaries like GSK. In this episode, I sit down with Christopher Austin, Head of Research Technologies at GSK, to explore how AI, data science, and cutting-edge digital capabilities are revolutionizing drug discovery and development. Chris shares how GSK is harnessing vast datasets, AI-driven insights, and genetic validation to speed up the identification of promising drug targets. We discuss how computational biology and machine learning are dramatically reducing the time it takes to develop new treatments—sometimes cutting discovery timelines in half. From selecting the right molecular designs to improving patient identification for clinical trials, technology is streamlining the entire R&D process, increasing success rates, and ultimately bringing life-saving medicines to patients faster. We also dive into the role of generative AI in modeling diseases, designing antibodies, and optimizing clinical trials. With AI now shaping everything from drug formulation to patient recruitment, we explore what this means for the future of medicine and the ethical considerations that come with such rapid advancements. How will AI-driven drug discovery change the pharmaceutical industry in the next decade? What challenges remain in integrating these new technologies into traditional research models? And what does all of this mean for patients and the future of healthcare? Tune in to hear how GSK is leading the charge in transforming medicine through technology.

Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis' unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.Links:Explore Prellis Biologicshttps://prellisbio.com/Understand AlphaFold, DeepMind's AI model for predicting protein structureshttps://deepmind.google/alphafoldRead about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/ 

This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx's mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John's diverse experiences inform his approach as a leader.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to John02:01 John's background at GSK and his transition to drug discovery05:45 Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets 08:27 Genomic origins of newly-identified proteins and the process of finding them09:49 Developing the ProFoundry atlas and integrating data across assays 15:27 Different approaches to inferring protein links and association to disease17:13 Collaboration with Pfizer to find regulators in the context of obesity18:04 Developing novel antibody-drug conjugates for cancer treatment20:27 Clarifying causality in proteomic data21:59 Approaching novel targets while considering industrial and business factors25:19 John's background as a cardiologist and how that impacts his current work27:26 Tips for biotech companies looking to be noticed by pharma for collaborations30:30 Considerations for investigating new and different therapeutic modalities and techniques33:39 How John consistently reinforces the translational angle as a business leader36:24 Closing remarks and future direction for ProFound TherapeuticsFind out moreProFound Therapeutics (https://www.profoundtx.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future.  

This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the US? and Global start-ups: where is the innovation? In the first article, I take a snapshot of the US biotech market and some of the ongoing research coming out of the US. In the second, DDW editors take a look at some key global activity taking place around the world for drug discovery and life sciences start-ups.

WisBusiness: the Podcast with Prof. Jim Cook, Milwaukee Institute for Drug Discovery by wispolitics

In our first episode of 2025, our hosts, Chris Williams and Dave Thompson, have the pleasure of speaking to Fernando Garces, CEO and co-founder of BioGlyph. Leading us from the sunny climes of Portugal through the tropical paradise that is London, on route to the West Coast of the US and A, Fernando shares his evolving love of science through the heights of academia, into industry, and now as CEO of a software company he co-founded to improve the modeling of complex multispecifics. Important questions are unpacked throughout - is London really a tropical paradise? How long can we keep milking podcast episode titles that take advantage of the homophonic property of pharma and farm? Oh, and we have another surprising guest answer to the ‘Deschênes Dilemma'… It is not to quote G. K. Chesterton, a proper nailbiter!

Today's guest is Liran Belenzon, Co-founder and CEO of BenchSci. BenchSci is a global leader in AI solutions for preclinical R&D that helps decipher complex biomedical research using proprietary technology. Liran joins us to discuss how AI is transforming disease biology research, streamlining scientific workflows, and enabling better decision-making in pharmaceutical R&D. Liran shares insights into the biggest challenges facing drug discovery today, including the complexity of disease biology and the critical role AI plays in unraveling it. He breaks down how AI-driven knowledge graphs, ontological models, and multimodal AI systems are improving both the speed and quality of scientific research. This episode is sponsored by BenchSci. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Generate:Biomedicines is pioneering generative biology at the intersection of AI and medicine, creating breakthrough therapeutics by designing and testing millions of proteins simultaneously.

In this episode of the VetFolio Voice podcast, we're joined by renowned veterinary surgeon and educator Dr. Terry Fossum, who probes a number of complex issues in veterinary medicine. Dr. Fossum takes us on a deep dive into the world of drug discovery, sharing insights on the challenges and breakthroughs in developing new treatments for animals. Noting that veterinary education shouldn't stop at graduation, Dr. Fossum emphasizes the importance of continuous learning in advancing veterinary care. Dr. Fossum also weighs in on the evolving debate between supplements and drugs, so that you can better understand how to choose the best option for your patients—and how to manage long-term care using both approaches. Whether you're a seasoned vet or just starting out, this episode offers invaluable advice on improving patient outcomes and ensuring lasting health through informed decisions.

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI's drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can artificial intelligence help craft new medicines?” Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. In the first article, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within drug discovery and the company's work in the antibodies sector. In the second article, Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before.

As we head into the second half of the decade chock-full of massive change and innovation, The Reboot Chronicles wanted to know how higher education will reboot itself to not just meet our global challenges—but lead the way. While AI has broken the rules of growth and innovation, supercharging most business sectors whether they wanted it or not, most of our institutions are not riding the wave or even keeping up—except for a few.One of America's top universities that is ahead of the pack, bucking the trends, and hitting on all cylinders is Vanderbilt University. Vanderbilt's top dog, Chancellor Daniel Diermeier, joins us on this action packed episode with a behind the scenes tour of how they are rebooting higher education and preparing to teach future innovators to make an impact.An internationally renowned political scientist, management scholar, and visionary business leader, under Daniel's leadership Vanderbilt has been on a tear, with its endowment booming to $10B and over $1B in external research funding, setting record for licensing revenues—surpassing traditional innovation leaders Stanford and MIT. Listen in as we unpack how he is breaking down culture walls and empowering people with the right to win to drive radical collaboration—and his personal reboot that may help you decide to follow your heart.#growth #innovation #therebootchronicles #deandebiase #BuildBuyBorrow #HigherEducation #UniversityLeadership #EducationReform #InnovationInEducation #FutureOfUniversities #ArtificialIntelligence #AIInEducation #AIInnovation #TechLeadership #AIResearch #BiomedicalResearch #DrugDiscovery #PersonalizedMedicine #MedicalAI #HealthcareInnovation #VanderbiltUniversity #DanielDiermeier

In today's episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director of the USC Center for Molecular Pathway and Drug Discovery, and co-director of the USC Norris Center for Cancer Drug Development in Los Angeles. In our exclusive interview, Dr Lenz discussed the prevalence of RAS mutations in PDAC, the importance of biomarker testing, current treatment strategies for patients with RAS-mutant PDAC, and potential future treatment advances for patients with this disease.

Mika Newton and Tom Neyarapally discuss how AI is changing the landscape of drug discovery. They examine the role of machine learning, patient data, and computational tools in accelerating the process, reducing costs, and improving the chances of developing effective treatments. The conversation covers how AI-driven screening, drug repurposing, and real-world data integration are helping to overcome traditional challenges in bringing new therapies to patients faster. They also examine the potential for collaboration between AI technology and clinical expertise to drive future breakthroughs in medicine.

AI is transforming the world, but how significantly has it revolutionized healthcare? Can it expedite drug discovery, personalize treatment, and reduce costs? In this episode of "Unusual Suspects," we speak with Mr. Raj Babu, the founder and CEO of Agilisium, a leader in AI-driven healthcare innovation. Raj discusses how Agilisium empowers researchers and pharmaceutical companies to address complex challenges, from digitizing supply chains for cell and gene therapy to facilitating breakthroughs in neonatal cancer research. He also discusses the ethical implications of AI, the democratization of innovation, and how startups are creating a more level playing field in healthcare. Take a listen!

Welcome to the Olink® Proteomics in Proximity podcast!  Below are some useful resources mentioned in this episode:  Olink® Reveal, accessible NGS-based proteomics for every lab: https://olink.com/products/olink-revealOlink tools and software·       Olink® Explore 3072, the platform utilized by the UK Biobank to measure ~3000 proteins in plasma: https://olink.com/products-services/explore/·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies   Subscribe to the podcast on your favorite player or app:Apple Podcasts: https://apple.co/3T0YbSm   Spotify Podcasts: https://open.spotify.com/show/2sZ2wxO...   Google Podcasts: https://podcasts.google.com/feed/aHR0...   Amazon Music: https://music.amazon.com/podcasts/d97...   Podcast Addict: https://podcastaddict.com/podcast/409...   Deezer: https://www.deezer.com/show/5178787   Player FM: https://player.fm/series/series-3396598   In case you were wondering, Proteomics in Proximity refers to the principle underlying Olink technology called the Proximity Extension Assay (PEA). More information about the assay and how it works can be found here: https://bit.ly/3Rt7YiY  For any questions regarding information Olink Proteomics, please email us ...

A recent study in the journal Nature unveiled new proteins that can neutralize the deadliest of snake venoms. They're “new” in that they aren't found in nature—they were created in a lab, dreamed up by AI.Using AI to discover, or design, the building blocks of drugs is a fast-growing area of research. Another team of scientists out of Philadelphia is using AI to discover new antibiotics by resurrecting long-lost molecules from extinct species like neanderthals and woolly mammoths.We know what you're thinking: It sounds too sci-fi to be true.Flora Lichtman talks with two pioneers in the field about how AI is supercharging drug discovery: Dr. César de la Fuente, bioengineer and presidential associate professor at the University of Pennsylvania in Philadelphia, and Nobel laureate Dr. David Baker, director of the Institute for Protein Design and professor at the University of Washington in Seattle.Transcripts for each segment will be available after the show airs on sciencefriday.com.For our Los Angeles listeners: We're working on a story about the toxins left behind by the fires and we want to hear from you. How is this affecting you? Are you worried about the air and water and soil? How are you approaching clean-up? And what questions do you have?Leave us a voicemail at 1-646-767-6532 or send us an email at scifri@sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Mika Newton and Tom Neyarapally explore how advancements in AI are accelerating the development of new algorithms, improving target discovery, and enhancing high-throughput screening. The conversation highlights the challenges and opportunities in aggregating innovative technologies, the convergence of AI tools in healthcare, and the potential for personalized and economically viable drug development.

In this episode of the Life Science Success podcast, my guest is Gayathri Devi Raghupathy, a scientific strategist and AI innovator with a Ph.D. in Molecular Biology. As the VP of Scientific and Business Strategy at KOGNITIC, Gayathri has been instrumental in developing AI-driven competitive intelligence platforms for oncology and immunology, working with major pharmaceutical companies to drive innovation in drug development processes.   00:00 Introduction to Life Science Success Podcast 00:35 Sponsor Message: D3 Digital Media Marketing 01:24 Guest Introduction: Gayathri's Journey in Molecular Biology and AI 02:11 Gayathri's Career Path and Transition to AI 11:33 Role and Impact of KOGNITIC in Life Sciences 19:06 Challenges and Future of AI in Drug Development 24:07 Balancing Scientific Accuracy with Business Strategy 28:28 Emerging Trends and Technologies in AI 36:28 Personal Insights and Reflections 44:02 Conclusion and Podcast Information

Welcome to the Olink® Proteomics in Proximity podcast!   Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore 3072, the platform utilized by the UK Biobank to measure ~3000 proteins in plasma: https://olink.com/products-services/explore/·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  Press release and news story from UK Biobank:https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/launch-of-world-s-most-significant-protein-study-set-to-usher-in-new-understanding-for-medicine https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/dataset-of-thousands-of-proteins-marks-landmark-step-for-research-into-human-health https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies News stories:Today Programme – Professor Rory Collins live on programme, timestamp 02:36:37   Times – ‘Game-changing' study of blood proteins will help fight disease Independent – World's largest proteins study ‘invaluable' for understanding disease – experts Daily Mail – How Alzheimer's could be diagnosed a DECADE earlier following huge study of blood proteins Mirror – New blood test reveals risk of developing different diseases in 'new frontier of science' Science – Seeking disease insights, UK Biobank launches largest study of human proteinsTechnology Networks – UK Biobank Launches Largest Proteomics Study for Disease Research Chemical and Engineering News – Pharma firms team up to study UK proteomics data  Links to referred episodes:  • Evan – Episode 20:     https://share.transistor.fm/s/f795811e    https://open.spotify.com/episode/6lv5GA8hZCgDvujlBltS9f?si=36a29e6cfa4b4fae     https://podcasts.apple.com/us/podcast/how-proteomics-is-shaping-pharma-strategies/id1645900688?i=1000635040581 • Chris – Episode 16:     https://share.transistor.fm/s/255ad207     https://open.spotify.com/episode/0oe0S6zI8cryUtgZTjGlRq?si=8a7b0323b1364b96     https://podcasts.apple.com/us/podcast/interview-about-the-uk-biobank-with-dr-christopher-whelan/id1645900688?i=1000622521524  Subscribe to the podcast on your favorite player or app:Apple Podcasts: https://apple.co/3T0YbSm   Spotify Podcasts: https://open.spotify.com/show/2sZ2wxO...   Google Podcasts: https://podcasts.google.com/feed/aHR0...   Amazon Music:

Plus, Open AI CEO Sam Altman is sued by his sister. And Meta tests eBay crossovers on Facebook Marketplace. James Rundle hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Ross Katz sits down with Fred Manby, Co-Founder and Chief Technology Officer of Iambic Therapeutics, to explore how cutting-edge AI technologies are reshaping the landscape of drug discovery. From building advanced machine learning platforms to designing user-friendly interfaces for scientists, Fred shares insights into the company's approach to tackling some of the biggest challenges in biotech. Fred dives into the unique capabilities of Iambic's Enchant multi-modal transformer model, its differentiation from other biological foundation models, and the importance of aligning model architecture with data creation and acquisition in modern drug discovery. We also discuss Iambic's data-driven approach to developing oncology drugs, the exciting possibilities of incorporating new modalities like imaging, and the recent breakthroughs in protein-ligand structure prediction with NeuralPLexer3.  Highlights: Enchant Multi-Modal Transformer Model: How it systematically surpasses state-of-the-art molecular AI technologies.Uncertainty Quantification: The role of probabilities and predictions in streamlining drug discovery. Interface Design for Scientists: Iambic's approach to integration between AI platforms and experimental workflows. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Iambic's work on their website  Connect with Fred Manby on LinkedIn

Stock market update for January 8, 2025.

Episode 90. Barry Bunin is the CEO and President at Collaborative Drug Discovery, which he founded 20 years ago. Prior to that, Barry was an Entrepreneur in Residence at Eli Lilly. He completed his PhD in Bioorganic Chemistry at UC Berkeley and his bachelor's degree in chemistry at Columbia University. To learn more about CDD: https://www.collaborativedrug.com/ai-drug-discovery#Bioisosteric-Suggestionshttps://www.collaborativedrug.com/curves#Calculationshttps://www.collaborativedrug.com/automation

Machine learning and generative AI are transforming the ways we live and work, but how do these tools fit into the landscape of drug discovery? In our season 5 finale, co-host Danielle Mandikian is joined by Rich Bonneau, Vice President of Machine Learning, Drug Discovery, to break down the fast-paced, expansive – and sometimes perplexing – world of AI and biology. Together, they discuss the importance of integrating machine learning with traditional lab work, the need for minimizing bias in datasets, and the exciting potential for these technologies to unlock better and more complex medicines. Read the full text transcript at www.gene.com/stories/ai-and-the-future-of-medicine